Showing 20 of 36 recruiting trials for “systemic-vasculitis-associated-with-glomerulopathy”
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
RecruitingNCT07258524 ↗
PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
👨⚕️ David Massicotte-Azarniouch, MD, MSc, The Ottawa Hospital📍 2 sites📅 Started Nov 2025View details ↗
RecruitingNCT07151521 ↗
(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Jan 2025View details ↗
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
👨⚕️ Maria Antonietta D'Agostino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS📍 1 site📅 Started Nov 2024View details ↗
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
👨⚕️ Masayoshi Harigai, MD, PhD, International University of Health and Welfare📍 22 sites📅 Started Nov 2024View details ↗
RecruitingNCT06696027 ↗
AYLo - AutoimmunitY and Loss of y
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
RecruitingNCT06508346 ↗
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
👨⚕️ Jianhua Mao, PhD, Children's Hospital, Zhejiang University School of Medicine📍 1 site📅 Started Aug 2024View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →